55 results about "Management of ulcerative colitis" patented technology

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis, multiple sclerosis, autoimmune thyroiditis, allergic rhinitis, colon polyps/colon cancer and asthma can be treated by the methods and compositions disclosed therein.

The invention relates to a compound Chinese medicinal preparation for treating ulcerative colitis. The compound Chinese medicinal preparation comprises the following Chinese medicinal raw materials in weight by percentage: 8-12 percent of codonopsis pilosula, 16-24 percent of astragalus root, 13-17 percent of tuckahoe, 8-12 percent of bighead atractylodes rhizome, 8-12 percent of costus root, 8-12 percent of white paeony root, 5-7 percent of coptis root, 13-17 percent of Chinese pulsatilla root and 5-7 percent of liquoric root. A preparation method of the compound Chinese medicinal preparation comprises the following steps of: cleaning the 9 medicinal materials; mixing in proportion; adding water in an amount which is 5-7 times the total weight of the medicinal materials or ethanol in an amount which is 70 percent of the volume ratio to decoct for 3 times, 1 hour each time; combining decoction for 3 times; filtering; and concentrating to obtain liquid extract with specific gravity of 1.17 at the temperature of 60 DEG C. By adopting the conventional reparation process, the preparation can be prepared into any one pharmaceutically said formulation, such as tablets, capsules, granules, dripping pills, oral liquid, pills, syrup, dispersible tablets and effervescent tablets. The compound Chinese medicinal preparation for treating the depression prepared by the invention has the advantages of obvious curative effect and no adverse effect, and can be applied to treatment of the ulcerative colitis in a large range.

The invention relates to a traditional Chinese medicine suppository for treating ulcerative colitis, which can be used for solving the treatment problem of the ulcerative colitis effectively, and adopts the technical proposal that the suppository is prepared from the following medicaments: 20 to 30 grams of radix astragali, 10 to 15 grams of radix codonopsitis, 20 to 30 grams of atractylis ovata, 15 to 20 grams of tuckahoe, 15 to 20 grams of white paeony root, 20 to 30 grams of purslane, 20 to 30 grams of raw burnet and mixed fatty acid glyceride. The preparation method comprises the following steps: adding water to the radix astragali, the radix codonopsitis, the atractylis ovata, the tuckahoe, the white paeony root, the purslane and the raw burnet to decoct by the prior method, and drying the mixture to prepare traditional Chinese medicine extract powder, adding the traditional Chinese medicine extract powder in the dissolved and mixed fatty acid glyceride as a matrix, wherein each 600 grams of the dissolved and mixed fatty acid glyceride is added with 250 grams of the traditional Chinese medicine extract powder; stirring the mixture evenly, adding the mixture in a mould coated with soap tincture for cooling, leveling and taking out to obtain the suppository, wherein each suppository weighs 1.7 g. The suppository has functions of invigorating the spleen to arrest diarrhea, cooling blood, arresting blood and removing blood stasis, and has the advantages of convenient use and good curative effect.

A medicine for treating ulcerative colitis is characterized by being prepared from the following raw materials by weight: 4-12 g of phellodendron, 4-12 g of coptis, 10-30 g of radix astragali, 10-30 g of atractylodes macrocephala, 10-30 g of sophora japonica L., 10-30 g of radix paeoniae alba, 10-30 g of radix glycyrrhizae, 15-25 g of poria cocos, 10-20 g of sanguisorba officinalis, and 4-12 g of banksia rose. The medicine is prepared by cleaning, drying, grinding into powders, screening, refining honey, preparing into a medicine, preparing into medicine pills and the like. The medicine has the advantages of being simple in preparation, convenient to take, substantial in treatment effect, free of toxic and side effects, and low in price, and is especially suitable for treating ulcerative colitis.

The invention discloses application of lactobacillus plantarum YS4, of which the preservation number is CCTCC NO: M2016750, in preparation of food or drugs for preventing ulcerative colitis, so that an application range of the lactobacillus plantarum YS4 is widened, and an application value of the lactobacillus plantarum YS4 is improved; moreover, new hope is brought for treatment or health care on the ulcerative colitis.

The present invention relates to a use of ZFP91 based on the functions of ZFP91 (Zinc Finger Protein 91) and the interaction of ZFP91 with NF-κB (Nuclear factor kappa B) signal transduction pathway proteins, more precisely a method to inhibit the activation of NF-κB alternative pathway by regulating ZFP91 activation, to inhibit tumor growth by inhibiting the transcription factor HIF-1 (hypoxia inducible factor-1) activation, to inhibit cancer malignancy by inhibiting angiogenesis, or reversely a method to increase the activation of NF-κB alternative pathway or to increase angiogenesis by increasing activation of HIF-1. The method of regulating ZFP91 activation of the present invention can increase or reduce HIF-1α stability by increasing or reducing the activation of NF-κB alternative pathway, so that it can be effectively used for the development of an anticancer agent, a therapeutic agent for arthritis, a therapeutic agent for ulcerative colitis, an anti-inflammatory agent and an angiogenesis inducer.

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis and multiple sclerosis can be treated by the methods and compositions disclosed therein.

The present invention is directed to a pharmaceutical composition for the treatment of steroid depending and/or steroid resistive ulcerative colitis. The pharmaceutical composition, which is administered to treat steroid depending and/or steroid resistive ulcerative colitis, contains, as the active ingredients, at least one compound selected from a group consisting of tetracyclines, penicillins, and nitroimidazoles.

The invention relates to the technical field of traditional Chinese medicine processing and natural product extraction, in particular to a method for preparing ellagic acid from terminalia chebula pulp processed through being heated by sand and application. The method of preparing the ellagic acid comprises the following steps of putting the terminalia chebula fruits into river sand being 220 DEGC to 260 DEG C; performing heating for 5 to 9 min; peeling pulp; crushing the pulp into medicine powder; performing reflux extraction by ethanol; then, performing gradient elution by the ethanol at different concentrations by using a macroporous adsorption resin method; collecting eluent with the ethanol concentration being 90 percent; recovering the ethanol; and drying residues at reduced pressure to obtain an ellagic acid product. Through the optimization on a processing method and process parameters, the content of the ellagic acid in raw materials is greatly improved; and through the reflux extraction through the ethanol, and then through elution through ethanol solutions by the macroporous adsorption resin method, the cost is effectively reduced, and the yield and the purity of the ellagic acid product are improved. The ellagic acid prepared by the method is used for treating ulcerative colitis, is safe and effective, and is favorable for improving the life quality of patients.

The invention discloses an application of total saponins of panax japonicus in preparation of ulcerative colitis resisting medicines. According to the application, the prevention and treatment action and action mechanism of the total saponins of panax japonicus to dextran sulfate sodium induced mouse ulcerative colitis are researched through a series of tests, i.e., extracting the total saponins of panax japonicus, carrying out an acute toxicity test on the total saponins of panax japonicus, modeling a mouse acute ulcerative colitis model and observing the therapeutic action of the total saponins of panax japonicus on ulcerative colitis, and the influence on NF-[kappa]B and PPAR-gamma signal channels caused by the total saponins of panax japonicus is disclosed for the first time. The total saponins of panax japonicus have the effects of treating both symptoms and root causes and being safe and effective during the treatment of the ulcerative colitis.

The invention provides tannic acid curcumin nanoparticles and a preparation method and use thereof, and belongs to the field of biomedical materials. The nanoparticles are prepared from the following raw materials in parts by weight: 80-100 parts of human serum albumin, 10-50 parts of genipin, 1-20 parts of a medicine and 10-50 parts of tannic acid. The medicine is preferably curcumin. The raw materials of the tannic acid drug-loaded nanoparticles are derived from food-grade materials and toxicity of the tannic acid drug-loaded nanoparticles is far lower than that of other synthesized chemical nano materials. The nanoparticles have good stability and high encapsulation efficiency and drug loading rate. More importantly, the nanoparticles have a targeting function on lesion colons, can be prevented from being destructively influenced by the stomach environment, and have an effect superior to that of other nano drug delivery systems reported before. Therefore, the tannic acid curcumin nanoparticles are a more promising oral administration system for treating colonic parts, especially ulcerative colitis.

The invention belongs to the technical field of medicine, and particularly relates to application of dronedarone to preparation of a medicine for preventing and treating colitis. In oder to mine a new compound for treating ulcerative colitis, the invention discovers by research of the treatment effect of the compound dronedarone on DSS-induced ulcerative colitis mice that the dronedarone has the treatment effect on the ulcerative colitis of the DSS-induced mice , and is expected to be applied to prevention and treatment of the ulcerative colitis.

The invention discloses a traditional Chinese medicine for treating ulcerative colitis and relates to the technical field of Chinese herbal medicines. The traditional Chinese medicine of the inventioncomprises the following raw materials (by weight): 25-35 parts of Radix Astragali, 15-25 parts of radix hedysari, 8-12 parts of pseudostellaria root, 15-25 parts of sweet wormwood, 4-8 parts of anemarrhena, 4-8 parts of cinnamon, 25-35 parts of sargentodoxa vine, 25-35 parts of patrinia herb, 8-12 parts of garden burnet, 8-12 parts of garden burnet root, 12-18 parts of tortoiseshell, 12-18 partsof turtle shell, 25-35 parts of Japanese honeysuckle stem, 12-18 parts of carbonized catnip, 4-8 parts of frankincense and 4-8 parts of myrrh. The therapeutic effect of the traditional Chinese medicine for treating 50 cases of ulcerative colitis is as follows: after treatment for one treatment course, the traditional Chinese medicine takes effect for patients in 32 cases of the 50 cases, is effective in 15 cases and is ineffective in 3 cases, and the total effective rate of the traditional Chinese medicine is 94%. The traditional Chinese medicine for treating ulcerative colitis can improve clinical symptoms of ulcerative colitis, has obvious curative effects, and has little side-effect.

The present invention relates to a traditional Chinese medicine composition for treating ulcerative colitis. The traditional Chinese medicine composition comprises 27-33 parts of verbena officinalis,27-33 parts of herba portulacae, 27-33 parts of humifuse euphorbia herb, 12-18 parts of betel nut, 12-18 parts of immature bitter oranges and 12-18 parts of angelica sinensis. The present invention also relates to an application of the traditional Chinese medicine composition. A therapeutic effect and a mechanism of the traditional Chinese medicine composition for the ulcerative colitis are studied by establishing a rat ulcerative colitis model. An experiment proves that the traditional Chinese medicine composition can significantly improve DAI score and colon tissue pathological injury of UCrats, at the same time can also significantly inhibit activation of I kappa B/NF-kappa B, thus reduces levels of IL-1 beta, TNF-alpha, etc., inhibits inflammation, and also has an effect significantlybetter than that in a SASP group.

The invention provides a new medical use of mimics of manganese superoxide dismutase (MnSODm), namely an application in the preparation of an ulcerative colitis (UC) treatment medicine. Observation on the treatment effect of the MnSODm compound on the 2,4,6-trinitrobenzene sulfonic acid (TNBS) induced rat UC indicates that the MnSODm has an obvious treatment effect on the TNBS induced rat UC; and therefore, the MnSODm can be used for preparing UC treatment medicines, namely that the MnSODm is made into pharmaceutically acceptable preparations by taking the MnSODm as an active ingredient according to conventional processes and accessories.